A randomized, double-blind, placebo-controlled trial of anti-interleukin-13 monoclonal antibody rpc4046 in patients with eosinophilic esophagitis

This study evaluated efficacy and safety of 2 dose levels of RPC4046 compared to placebo (PBO).

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: I. Hirano, M. Collins, Y. Assouline-Dayan, L. Evans, S. Gupta, A. Schoepfer, A. Straumann, C. Rodriguez, S. Hua, E. Dellon Tags: A400 Source Type: research